183 related articles for article (PubMed ID: 38391914)
1. Molecular Characterization and Subtyping of Breast Cancer Cell Lines Provide Novel Insights into Cancer Relevant Genes.
Pommerenke C; Nagel S; Haake J; Koelz AL; Christgen M; Steenpass L; Eberth S
Cells; 2024 Feb; 13(4):. PubMed ID: 38391914
[TBL] [Abstract][Full Text] [Related]
2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterisation of cell line models for triple-negative breast cancers.
Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
[TBL] [Abstract][Full Text] [Related]
4. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
Watson J; Wang T; Ho KL; Feng Y; Mahawan T; Dobbin KK; Zhao S
Breast Cancer Res; 2023 Oct; 25(1):114. PubMed ID: 37789381
[TBL] [Abstract][Full Text] [Related]
5. The Hematopoietic TALE-Code Shows Normal Activity of IRX1 in Myeloid Progenitors and Reveals Ectopic Expression of IRX3 and IRX5 in Acute Myeloid Leukemia.
Nagel S; Pommerenke C; Meyer C; MacLeod RAF
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328612
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
7. The Breast Cancer Single-Cell Atlas: Defining cellular heterogeneity within model cell lines and primary tumors to inform disease subtype, stemness, and treatment options.
Dave A; Charytonowicz D; Francoeur NJ; Beaumont M; Beaumont K; Schmidt H; Zeleke T; Silva J; Sebra R
Cell Oncol (Dordr); 2023 Jun; 46(3):603-628. PubMed ID: 36598637
[TBL] [Abstract][Full Text] [Related]
8. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
Tan X; Li Z; Ren S; Rezaei K; Pan Q; Goldstein AT; Macri CJ; Cao D; Brem RF; Fu SW
Breast Cancer Res; 2019 Aug; 21(1):89. PubMed ID: 31391072
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
12. ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer.
Shatnawi A; Ayoub NM; Alkhalifa AE
Clin Breast Cancer; 2021 Aug; 21(4):e319-e331. PubMed ID: 33334698
[TBL] [Abstract][Full Text] [Related]
13. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B; Bottai G; Lehmann-Che J; Kéri G; Orfi L; Iwamoto T; Desmedt C; Bianchini G; Turner NC; de Thè H; André F; Sotiriou C; Hortobagyi GN; Di Leo A; Pusztai L; Santarpia L
Mol Oncol; 2014 May; 8(3):508-19. PubMed ID: 24462521
[TBL] [Abstract][Full Text] [Related]
15. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer.
Lee SE; Lee HS; Kim KY; Park JH; Roh H; Park HY; Kim WS
Sci Rep; 2019 Jul; 9(1):10966. PubMed ID: 31358837
[TBL] [Abstract][Full Text] [Related]
17. LncRNA LUCAT1/miR-181a-5p axis promotes proliferation and invasion of breast cancer via targeting KLF6 and KLF15.
Liu Y; Cheng T; Du Y; Hu X; Xia W
BMC Mol Cell Biol; 2020 Sep; 21(1):69. PubMed ID: 32998707
[TBL] [Abstract][Full Text] [Related]
18. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
19. Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?
da Silva FC; de Melo Neto AB; Martins CA; de Sousa Cardoso TC; de Souza Gomes M; de Araújo TG; Fürstenau CR
Purinergic Signal; 2022 Mar; 18(1):123-133. PubMed ID: 34741235
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.
Jiang G; Zhang S; Yazdanparast A; Li M; Pawar AV; Liu Y; Inavolu SM; Cheng L
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):525. PubMed ID: 27556158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
